Listed

Vistagen Therapeutics, Inc.

VTGNNasdaqCIK 1411685HealthcareFiscal year ends Mar 31

Latest reported revenue, Q1 FY2027$1.5mRevenue, Q1 FY2027, three months to 2026-06-30$1.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-Q filed 2026-08-14, accession 0001628280-26-057116.Report this figureThree months to Jun 30, 2026, from the 10-Q filed Aug 14, 2026.

Latest quarter: Q1 FY2027

Three months to Jun 30, 2026, against the same quarter a year earlier.

  • Revenue$1.5mRevenue, Q1 FY2027, three months to 2026-06-30$1.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-Q filed 2026-08-14, accession 0001628280-26-057116.Report this figure+504.9% on a year earlier
  • Gross marginnot reported (Gross profit not reported)No year-earlier figure to compare
  • Operating margin−904.3%Operating margin, Q1 FY2027, three months to 2026-06-30. operating income / revenueOperating income: −$13.3m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-14, accession 0001628280-26-057116.Revenue: $1.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-Q filed 2026-08-14, accession 0001628280-26-057116.Report this figure+5572.7 pts on a year earlier
  • Net margin−882.8%Net margin, Q1 FY2027, three months to 2026-06-30. net income / revenueNet income: −$13.0m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-14, accession 0001628280-26-057116.Revenue: $1.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-Q filed 2026-08-14, accession 0001628280-26-057116.Report this figure+5303.7 pts on a year earlier
  • Diluted EPS−$0.30Diluted EPS, Q1 FY2027, three months to 2026-06-30−$0.30 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-14, accession 0001628280-26-057116.Report this figure+36.2% on a year earlier
  • Free cash flownot reported (Capital expenditure not reported)No year-earlier figure to compare

Last eight quarters

Full statements
Revenue$1.5mOperating margin −904.3%
Diluted EPS−$0.30, Q1 FY2027
Vistagen Therapeutics, Inc., key figures for the last eight quarters
Line itemUnitQ2 FY20252024-09-30Q3 FY20252024-12-31Q4 FY20252025-03-31Q1 FY20262025-06-30Q2 FY20262025-09-30Q3 FY20262025-12-31Q4 FY20262026-03-31Q1 FY20272026-06-30Shape over the periods
Revenue$k183Revenue, Q2 FY2025, three months to 2024-09-30$183.0k. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-Q filed 2025-11-13, accession 0001628280-25-052079.Report this figure234Revenue, Q3 FY2025, three months to 2024-12-31$234.0k. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-Q filed 2026-02-12, accession 0001628280-26-007718.Report this figure(15.0)Revenue, Q4 FY2025, three months to 2025-03-31−$15.0k. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-K filed 2026-06-15, accession 0001628280-26-043271. Derived: 12-month figure less the 9-month figure.Report this figure244Revenue, Q1 FY2026, three months to 2025-06-30$244.0k. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-Q filed 2026-08-14, accession 0001628280-26-057116.Report this figure258Revenue, Q2 FY2026, three months to 2025-09-30$258.0k. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-Q filed 2025-11-13, accession 0001628280-25-052079.Report this figure303Revenue, Q3 FY2026, three months to 2025-12-31$303.0k. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-Q filed 2026-02-12, accession 0001628280-26-007718.Report this figure465Revenue, Q4 FY2026, three months to 2026-03-31$465.0k. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-K filed 2026-06-15, accession 0001628280-26-043271. Derived: 12-month figure less the 9-month figure.Report this figure1,476Revenue, Q1 FY2027, three months to 2026-06-30$1.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-Q filed 2026-08-14, accession 0001628280-26-057116.Report this figure
Gross margin%not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)
Operating margin%(7774.3%)Operating margin, Q2 FY2025, three months to 2024-09-30. operating income / revenueOperating income: −$14.2m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-11-13, accession 0001628280-25-052079.Revenue: $183.0k. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-Q filed 2025-11-13, accession 0001628280-25-052079.Report this figure(6461.5%)Operating margin, Q3 FY2025, three months to 2024-12-31. operating income / revenueOperating income: −$15.1m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-02-12, accession 0001628280-26-007718.Revenue: $234.0k. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-Q filed 2026-02-12, accession 0001628280-26-007718.Report this figure96633.3%Operating margin, Q4 FY2025, three months to 2025-03-31. operating income / revenueOperating income: −$14.5m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-06-15, accession 0001628280-26-043271. Derived: 12-month figure less the 9-month figure.Revenue: −$15.0k. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-K filed 2026-06-15, accession 0001628280-26-043271. Derived: 12-month figure less the 9-month figure.Report this figure(6477.0%)Operating margin, Q1 FY2026, three months to 2025-06-30. operating income / revenueOperating income: −$15.8m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-14, accession 0001628280-26-057116.Revenue: $244.0k. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-Q filed 2026-08-14, accession 0001628280-26-057116.Report this figure(7772.5%)Operating margin, Q2 FY2026, three months to 2025-09-30. operating income / revenueOperating income: −$20.1m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-11-13, accession 0001628280-25-052079.Revenue: $258.0k. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-Q filed 2025-11-13, accession 0001628280-25-052079.Report this figure(6450.8%)Operating margin, Q3 FY2026, three months to 2025-12-31. operating income / revenueOperating income: −$19.5m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-02-12, accession 0001628280-26-007718.Revenue: $303.0k. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-Q filed 2026-02-12, accession 0001628280-26-007718.Report this figure(3595.1%)Operating margin, Q4 FY2026, three months to 2026-03-31. operating income / revenueOperating income: −$16.7m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-06-15, accession 0001628280-26-043271. Derived: 12-month figure less the 9-month figure.Revenue: $465.0k. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-K filed 2026-06-15, accession 0001628280-26-043271. Derived: 12-month figure less the 9-month figure.Report this figure(904.3%)Operating margin, Q1 FY2027, three months to 2026-06-30. operating income / revenueOperating income: −$13.3m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-14, accession 0001628280-26-057116.Revenue: $1.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-Q filed 2026-08-14, accession 0001628280-26-057116.Report this figure
Net margin%(7082.5%)Net margin, Q2 FY2025, three months to 2024-09-30. net income / revenueNet income: −$13.0m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-02-12, accession 0001628280-26-007718.Revenue: $183.0k. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-Q filed 2025-11-13, accession 0001628280-25-052079.Report this figure(6020.9%)Net margin, Q3 FY2025, three months to 2024-12-31. net income / revenueNet income: −$14.1m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-02-12, accession 0001628280-26-007718.Revenue: $234.0k. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-Q filed 2026-02-12, accession 0001628280-26-007718.Report this figure90900.0%Net margin, Q4 FY2025, three months to 2025-03-31. net income / revenueNet income: −$13.6m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-06-15, accession 0001628280-26-043271. Derived: 12-month figure less the 9-month figure.Revenue: −$15.0k. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-K filed 2026-06-15, accession 0001628280-26-043271. Derived: 12-month figure less the 9-month figure.Report this figure(6186.5%)Net margin, Q1 FY2026, three months to 2025-06-30. net income / revenueNet income: −$15.1m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-14, accession 0001628280-26-057116.Revenue: $244.0k. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-Q filed 2026-08-14, accession 0001628280-26-057116.Report this figure(7526.0%)Net margin, Q2 FY2026, three months to 2025-09-30. net income / revenueNet income: −$19.4m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-02-12, accession 0001628280-26-007718.Revenue: $258.0k. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-Q filed 2025-11-13, accession 0001628280-25-052079.Report this figure(6237.3%)Net margin, Q3 FY2026, three months to 2025-12-31. net income / revenueNet income: −$18.9m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-02-12, accession 0001628280-26-007718.Revenue: $303.0k. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-Q filed 2026-02-12, accession 0001628280-26-007718.Report this figure(3499.8%)Net margin, Q4 FY2026, three months to 2026-03-31. net income / revenueNet income: −$16.3m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-06-15, accession 0001628280-26-043271. Derived: 12-month figure less the 9-month figure.Revenue: $465.0k. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-K filed 2026-06-15, accession 0001628280-26-043271. Derived: 12-month figure less the 9-month figure.Report this figure(882.8%)Net margin, Q1 FY2027, three months to 2026-06-30. net income / revenueNet income: −$13.0m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-14, accession 0001628280-26-057116.Revenue: $1.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-Q filed 2026-08-14, accession 0001628280-26-057116.Report this figure
Diluted EPS$ per share(0.42)Diluted EPS, Q2 FY2025, three months to 2024-09-30−$0.42 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-11-13, accession 0001628280-25-052079.Report this figure(0.46)Diluted EPS, Q3 FY2025, three months to 2024-12-31−$0.46 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-02-12, accession 0001628280-26-007718.Report this figurenot reported (Diluted EPS not reported)(0.47)Diluted EPS, Q1 FY2026, three months to 2025-06-30−$0.47 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-14, accession 0001628280-26-057116.Report this figure(0.54)Diluted EPS, Q2 FY2026, three months to 2025-09-30−$0.54 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-11-13, accession 0001628280-25-052079.Report this figure(0.45)Diluted EPS, Q3 FY2026, three months to 2025-12-31−$0.45 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-02-12, accession 0001628280-26-007718.Report this figurenot reported (Diluted EPS not reported)(0.30)Diluted EPS, Q1 FY2027, three months to 2026-06-30−$0.30 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-14, accession 0001628280-26-057116.Report this figure
Free cash flow$knot reported (Capital expenditure not reported)not reported (Capital expenditure not reported)not reported (Capital expenditure not reported)not reported (Capital expenditure not reported)not reported (Capital expenditure not reported)not reported (Capital expenditure not reported)not reported (Capital expenditure not reported)not reported (Capital expenditure not reported)

Focus or hover a figure to see its XBRL concept, period and filing; each links to that filing. A figure marked d is derived: a quarter computed from year-to-date figures, such as the fourth quarter as the fiscal year less the nine months before it. A ratio reads not reported when any input is missing.

Last five fiscal years

Revenue$1.3mOperating margin −5683.7%
Diluted EPS−$1.83, FY2026
Free cash flow−$25.8m, FY2024
Vistagen Therapeutics, Inc., key figures for the last five fiscal years
Line itemUnitFY20222022-03-31FY20232023-03-31FY20242024-03-31FY20252025-03-31FY20262026-03-31Shape over the periods
Revenue$m1.1Revenue, FY2022, twelve months to 2022-03-31$1.1m. XBRL concept us-gaap:Revenues. 10-K filed 2023-06-28, accession 0001437749-23-018793.Report this figure(0.2)Revenue, FY2023, twelve months to 2023-03-31−$227.0k. XBRL concept us-gaap:Revenues. 10-K filed 2023-06-28, accession 0001437749-23-018793.Report this figure1.1Revenue, FY2024, twelve months to 2024-03-31$1.1m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-K filed 2025-06-17, accession 0001411685-25-000041.Report this figure0.5Revenue, FY2025, twelve months to 2025-03-31$486.0k. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-K filed 2026-06-15, accession 0001628280-26-043271.Report this figure1.3Revenue, FY2026, twelve months to 2026-03-31$1.3m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-K filed 2026-06-15, accession 0001628280-26-043271.Report this figure
Gross margin%not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)
Operating margin%(4308.3%)Operating margin, FY2022, twelve months to 2022-03-31. operating income / revenueOperating income: −$47.8m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2023-06-28, accession 0001437749-23-018793.Revenue: $1.1m. XBRL concept us-gaap:Revenues. 10-K filed 2023-06-28, accession 0001437749-23-018793.Report this figure26109.3%Operating margin, FY2023, twelve months to 2023-03-31. operating income / revenueOperating income: −$59.3m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2024-06-11, accession 0001411685-24-000022.Revenue: −$227.0k. XBRL concept us-gaap:Revenues. 10-K filed 2023-06-28, accession 0001437749-23-018793.Report this figure(3103.5%)Operating margin, FY2024, twelve months to 2024-03-31. operating income / revenueOperating income: −$33.0m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2025-06-17, accession 0001411685-25-000041.Revenue: $1.1m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-K filed 2025-06-17, accession 0001411685-25-000041.Report this figure(11517.1%)Operating margin, FY2025, twelve months to 2025-03-31. operating income / revenueOperating income: −$56.0m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-06-15, accession 0001628280-26-043271.Revenue: $486.0k. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-K filed 2026-06-15, accession 0001628280-26-043271.Report this figure(5683.7%)Operating margin, FY2026, twelve months to 2026-03-31. operating income / revenueOperating income: −$72.1m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-06-15, accession 0001628280-26-043271.Revenue: $1.3m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-K filed 2026-06-15, accession 0001628280-26-043271.Report this figure
Net margin%(4306.8%)Net margin, FY2022, twelve months to 2022-03-31. net income / revenueNet income: −$47.8m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2023-06-28, accession 0001437749-23-018793.Revenue: $1.1m. XBRL concept us-gaap:Revenues. 10-K filed 2023-06-28, accession 0001437749-23-018793.Report this figure26100.4%Net margin, FY2023, twelve months to 2023-03-31. net income / revenueNet income: −$59.2m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2024-06-11, accession 0001411685-24-000022.Revenue: −$227.0k. XBRL concept us-gaap:Revenues. 10-K filed 2023-06-28, accession 0001437749-23-018793.Report this figure(2759.6%)Net margin, FY2024, twelve months to 2024-03-31. net income / revenueNet income: −$29.4m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2025-06-17, accession 0001411685-25-000041.Revenue: $1.1m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-K filed 2025-06-17, accession 0001411685-25-000041.Report this figure(10579.8%)Net margin, FY2025, twelve months to 2025-03-31. net income / revenueNet income: −$51.4m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-06-15, accession 0001628280-26-043271.Revenue: $486.0k. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-K filed 2026-06-15, accession 0001628280-26-043271.Report this figure(5491.3%)Net margin, FY2026, twelve months to 2026-03-31. net income / revenueNet income: −$69.7m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-06-15, accession 0001628280-26-043271.Revenue: $1.3m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-K filed 2026-06-15, accession 0001628280-26-043271.Report this figure
Diluted EPS$ per sharenot reported (Diluted EPS not reported)(8.51)Diluted EPS, FY2023, twelve months to 2023-03-31−$8.51 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2024-06-11, accession 0001411685-24-000022.Report this figure(1.52)Diluted EPS, FY2024, twelve months to 2024-03-31−$1.52 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2025-06-17, accession 0001411685-25-000041.Report this figure(1.67)Diluted EPS, FY2025, twelve months to 2025-03-31−$1.67 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2026-06-15, accession 0001628280-26-043271.Report this figure(1.83)Diluted EPS, FY2026, twelve months to 2026-03-31−$1.83 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2026-06-15, accession 0001628280-26-043271.Report this figure
Free cash flow$m(45.5)Free cash flow, FY2022, twelve months to 2022-03-31. operating cash flow − capital expenditureOperating cash flow: −$45.3m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2023-06-28, accession 0001437749-23-018793.Capital expenditure: $200.4k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2022-06-23, accession 0001851734-22-000349.Report this figure(50.2)Free cash flow, FY2023, twelve months to 2023-03-31. operating cash flow − capital expenditureOperating cash flow: −$49.7m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2024-06-11, accession 0001411685-24-000022.Capital expenditure: $528.0k. XBRL concept us-gaap:PaymentsToAcquireProductiveAssets. 10-K filed 2024-06-11, accession 0001411685-24-000022.Report this figure(25.8)Free cash flow, FY2024, twelve months to 2024-03-31. operating cash flow − capital expenditureOperating cash flow: −$25.8m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2025-06-17, accession 0001411685-25-000041.Capital expenditure: $0. XBRL concept us-gaap:PaymentsToAcquireProductiveAssets. 10-K filed 2024-06-11, accession 0001411685-24-000022.Report this figurenot reported (Capital expenditure not reported)not reported (Capital expenditure not reported)

Focus or hover a figure to see its XBRL concept, period and filing; each links to that filing. A figure marked d is derived: a quarter computed from year-to-date figures, such as the fourth quarter as the fiscal year less the nine months before it. A ratio reads not reported when any input is missing.

Insider purchases and sales

All insider transactions

The last 20 open-market transactions reported on Form 4 (codes P and S). The reported price is the price per share the insider stated on the form: filing data, not a market price.

No open-market purchases or sales by insiders are in coverage from Nov 2024 to Oct 2026.

No open-market purchases or sales by insiders are in coverage for this company.

Funds that report holding it

All funds

From each manager's latest Form 13F, largest reported value first. Reported value is as filed at the quarter end: filing data, not a price. A put or call is an option position, not shares held.

Funds that report holding Vistagen Therapeutics, Inc.
FundQuarter endedReported valueSharesPut or callChange on the quarter before
Commodore Capital LP2026-06-30$630.2k2,788,620New+2,788,620
VANGUARD CAPITAL MANAGEMENT LLC2026-06-30$355.8k1,574,200Unchanged
TWO SIGMA INVESTMENTS, LP2026-06-30$191.6k847,992Added+378,373
RENAISSANCE TECHNOLOGIES LLC2026-06-30$165.1k730,500Added+439,200
Ikarian Capital, LLC2026-06-30$117.3k519,077Unchanged
AdvisorShares Investments LLC2026-06-30$99.1k438,643Added+161,533
SUSQUEHANNA INTERNATIONAL GROUP, LLP2026-06-30$95.5k415,400CallAdded+375,000
LUMINUS MANAGEMENT LLC2026-06-30$91.1k403,115Added+7,062
GEODE CAPITAL MANAGEMENT, LLC2026-06-30$82.5k365,002Reduced−88,389
ADAR1 Capital Management, LLC2026-06-30$79.4k351,141Reduced−400,000

Recent filings

All 898 filings

Reports and events: 10-K, 10-Q, 8-K, proxy statements and ownership schedules.

Vistagen Therapeutics, Inc., recent filings
FiledFormWhat it isAccession number
2026-10-0921:15 ET8-K5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits0001628280-26-065559
2026-09-2513:11 ET8-K7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits0001628280-26-063510
2026-09-2411:05 ET8-K8.01 Other events; 9.01 Financial statements and exhibits0001628280-26-063316
2026-09-2220:22 ET8-K8.01 Other events; 9.01 Financial statements and exhibits0001628280-26-063046
2026-09-1123:24 ET8-K5.07 Shareholder vote results; 9.01 Financial statements and exhibits0001628280-26-061445
2026-08-1420:12 ET10-QQuarterly reportPeriod 2026-06-300001628280-26-057116
2026-08-1412:40 ET8-K2.02 Results of operations; 9.01 Financial statements and exhibits0001628280-26-056953
2026-08-0620:16 ET8-K7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits0001628280-26-054341
2026-08-0520:04 ET8-K3.01 Delisting notice0001628280-26-053304
2026-07-3120:10 ETDEF 14AProxy statementPeriod 2026-07-310001628280-26-051404

Latest annual report

Form 10-K for the fiscal year ended Mar 31, 2026Filed Jun 15, 2026. Its page lists the documents and the extracted sections, such as Business and Risk factors.

Forecast league

Q2 FY2027, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by [object Promise].Forecast this quarter

About the filer

CIK
1411685
Tickers
VTGN
Exchange
Nasdaq
SIC code
2834 Pharmaceutical Preparations
Sector
Healthcare
Fiscal year ends
Mar 31
Incorporated in
NV
Filer category
Non-accelerated filer<br>Smaller reporting company
Former names
Excaliber Enterprises, Ltd. (to 2011-06-08)

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:39 ET. Listed shows no prices and gives no investment advice.